Feel Comfortable Holding PCSK9 Inhibitors During a Hospital Stay

May 2017

You'll hear buzz about using the PCSK9 inhibitors, evolocumab (Repatha) or alirocumab (Praluent), in patients with CV disease.

These injectable meds lower LDL cholesterol by about 60%...even in those on a high-intensity statin (atorvastatin 80 mg, etc).

Now evidence suggests that adding evolocumab to a statin in patients with CV disease and other risks (diabetes, etc) prevents one more CV event for every 74 patients treated for about 2 years.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Learn More

Already a subscriber? Log in

Not sold to individuals

HIV & AIDS Don't Give Partial HIV Regimens When Patients Are Hospitalized
Pediatrics Up to 80% of Babies With Neonatal Abstinence Syndrome May Need Medication
Sepsis Put the New Evidence About IV Vitamin C for Sepsis Into Perspective
Pregnancy Watch for Antibiotics to Avoid During Pregnancy
Antithrombotics Anticoagulation After an Intracranial Hemorrhage May Be Worth It in Atrial Fib
Vaccines Watch for Error-Prone Vaccine Abbreviations
Overactive Bladder Consider Stopping Overactive Bladder Meds During Hospitalization
Gastroenterology Be Aware Pancreatitis Is Possible Even After 1-2 Doses of Eluxadoline
Oral Health Discourage Antibiotic Prophylaxis Before Dental Work in Most Orthopedic Patients
Back Pain Promote Nondrug Therapy as Primary Treatment for Low Back Pain
Cholesterol Feel Comfortable Holding PCSK9 Inhibitors During a Hospital Stay

Feel Comfortable Holding PCSK9 Inhibitors During a Hospital Stay

Get unlimited access through an Enterprise license

Table of Contents